Longevity science is at a critical moment in time. In the wake of the COVID-19 pandemic investors, regulators and the medical community have woken up to the promise of ageing science and its potential to completely change how we prevent and treat disease. Advanced analytical tools are driving huge strides in our understanding of ageing biology and potential targets, and a number of high-profile fund raises are driving investor interest in the space.
Meanwhile, regenerative medicine goes from strength to strength, with the success of autologous stem cell treatments and renewed interest from the aesthetics industry. Gene therapies continue to show promise and inch closer to adoption. This is an incredibly exciting time to be a part of the growing longevity community.
The Longevity Leaders World Congress brings the world’s most prominent longevity scientists together, presenting the new research, responsible drug development and commercialisation. We’d love you to join us!
“A tremendous event!”
Omair Ahmed, Founder & Chief Product Officer, Neurometry
Longevity therapeutics market expected to reach $524 million by 2027
More than £1 billion invested in longevity biotech to date
3000+ longevity and regenerative medicine biotechs worldwide
667 active clinical trials for ageing as a disease worldwide
Cell and gene therapy market is forecast to reach $45 billion by 2028
£8.25 billion raised by cell and gene therapy companies in 2020
5000+ investors committing to longevity and regenerative medicine
More than 13,330 active cell therapy trials ongoing
Subscribe to hear speaker announcements, ticket offers and more